FIG 1.
Basic characteristics of patients with melanoma who have BRAFV600E, NRASQ61, and TERTprom mutations. Overview of (A) the training cohort (n = 96 patients with stage III and IV disease) and (B) the validation cohort (n = 35 patients with stage III and IV disease). In the upper panels, the demographic and tumor characteristics are represented. The middle panels show mutations detected by DNA sequencing in respective tumor samples. The lower panels correspond to respective plasma samples analyzed with droplet digital polymerase chain reaction. Radiologic tumor-load information at baseline is represented at the bottom of the panels. See also the Data Supplement. AJCC, American Joint Committee on Cancer; ID, identification; TL, tumor load.